Neuroimaging Core

神经影像核心

• 批准号: 10590710
• 负责人: Ann D. Cohen
• 金额: $ 64.97万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-15 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10590710
• 关键词: Acceleration; Address; Aging; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Amyloid; Behavioral Symptoms; Binding; Biological Markers; Biological Models; Brain; Brain imaging; Catalogs; Characteristics; Classification; Clinical; Clinical Trials; Clinical assessments; Collaborations; Data; Data Set; Databases; Dementia; Development; Diagnostic Imaging; Disease; Early Diagnosis; Early identification; Early treatment; Elderly; Eligibility Determination; Enrollment; Ensure; Environment; Epidemiology; Etiology; Evaluation; Faculty; Foundations; Functional Imaging; Funding; Genetic study; Gifts; Goals; Guanosine Triphosphate; Image; Imaging Device; Individual; Inflammation; Lesion; Ligands; MRI Scans; Magnetic Resonance Imaging; Measures; Medical Students; Methodology; Methods; Monitor; Nerve Degeneration; Neurobehavioral Manifestations; Outcome; Participant; Pathogenesis; Pathologic; Patients; Performance; Positioning Attribute; Positron-Emission Tomography; Postdoctoral Fellow; Procedures; Protein Isoforms; Public Health; Recommendation; Recording of previous events; Reproducibility; Research; Research Personnel; Risk Factors; Role; Sampling; Science; Stream; Structure; Structure of choroid plexus; Symptoms; Techniques; Technology; Training; Treatment Efficacy; Universities; Update; Work; amyloid imaging; clinical effect; comorbidity; data integrity; demented; education research; effective therapy; graduate student; gray matter; head-to-head comparison; imaging agent; imaging biomarker; imaging modality; imaging study; molecular imaging; neuroimaging; neuropathology; non-demented; novel; novel therapeutics; outreach; pre-clinical; protective factors; quality assurance; radiotracer; recruit; specific biomarkers; structural imaging; tau Proteins; tool; trial readiness; white matter

Core F: NIC Summary/Abstract The overall goal of the PITT-ADRC is to perform and promote research that increases our understanding of: 1) the etiology and pathogenesis of Alzheimer's disease (AD), 2) the mechanisms underlying the cognitive and behavioral symptoms of AD, and 3) to develop strategies that will result in effective early diagnoses and treatments for AD and related dementias. The Neuroimaging Core (NIC) will support these Center-wide goals by developing and applying cutting edge neuroimaging technology to studies that are focused on early and presymptomatic stages of the AD spectrum. As the search for preclinical biomarkers continues, it is becoming increasingly clear that functional and structural brain imaging data may hold the key to identifying the earliest pathological manifestations of AD prior to any meaningful clinical change. The NIC will continue to develop and distribute technology for acquiring and interpreting brain functional and structural imaging data in the support of AD research. The NIC will advance the Center goals by supporting and promoting research that increases our understanding of the etiology and pathogenesis of AD and facilitates the development of new therapies and methods for monitoring therapeutic efficacy. The NIC maintains data sets of structural imaging on individuals enrolled through the Clinical Core, and we continue to work on the expansion of leading-edge analytic technologies, and novel radiotracer ligands measured with Positron Emission Tomography (PET) (i.e., PiB, AV-1451 and GTP-1). The work of the NIC will accelerate efforts to identify early and presymptomatic AD by identifying imaging biomarkers to monitor the natural and treated history of the disease. The curated, “trial-ready” participant database will allow PITT-ADRC researchers to track biomarker-based clinical progression and to identify risk and protective factors. This database will also uniquely position the PITT-ADRC to identify potential participants based on specific biomarker characteristics. Finally, the NIC’s focus on quality assurance will ensure that neuroimaging methods are generating data measuring what they purport to measure and that the analysis stream retains the integrity of these data, ensuring that the statistical methodologies generate model that are biologically meaningful.

核心F：NIC摘要/摘要 Pitt-ADRC的总体目标是进行和促进研究，以增加我们的 理解：1）阿尔茨海默氏病的病因和发病机理（AD），2） AD的认知和行为症状，以及3）制定将早期生效的策略 AD和相关痴呆症的诊断和治疗。神经影像核（NIC）将支持这些 通过开发和应用前沿神经影像技术来研究的中心目标 专注于AD光谱的早期和前胞一次。 随着寻找临床前生物标志物的搜索继续，越来越清楚该功能和 结构性脑成像数据可能是确定AD先验最早病理表现的关键 任何有意义的临床变化。 NIC将继续开发和分发技术来吸收和 解释大脑功能和结构成像数据，以支持AD研究。 NIC会进步 通过支持和促进研究，使我们对病因的理解和 AD的发病机理并促进了新疗法的开发和监测治疗方法 功效。 NIC对通过临床核心入学的个体进行结构成像的数据集， 我们继续致力于扩展前沿分析技术和新颖的放射性配体 用正电子发射断层扫描（PET）（即PIB，AV-1451和GTP-1）测量。 NIC的工作将通过识别来加速识别早期和抑制性广告的努力 成像生物标志物以监测疾病的自然和治疗史。精选的“准备就绪” 参与者数据库将允许Pitt-ADRC研究人员跟踪基于生物标志物的临床进展和 确定风险和保护因素。该数据库还将唯一地定位Pitt-ADRC以识别潜力 基于特定生物标志物特征的参与者。最后，NIC专注于质量保证将 确保神经影像学方法正在生成数据，以衡量其旨在衡量的内容，并且 分析流保持这些数据的完整性，确保统计方法生成模型 在生物学上有意义。